MTP Building US Commercial Ops On Edaravone
This article was originally published in PharmAsia News
Japanese mid-sized firm Mitsubishi Tanabe Pharma is building up its independent US commercial operations with a view to conducting the in-house marketing of new products, starting with an ALS therapy.
You may also be interested in...
The arrival of the first drug for ALS in more than 20 years in the US will also be a boost to its originator Mitsubishi Tanabe's American ambitions.
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.